DOSSIER · 13F-HR · Q2 2026

Commodore Capital LP

$1.7B in tracked AUM across 33 positions as of Q2 2026.

CC
CIK 0001831942 · last filed Jun 30, 2026
Total AUM
$1.7B
as of Q2 2026
Holdings
33
positions
Whale Score
75
75
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Commodore Capital LP SEC 13F Filing
Portfolio Overview

Commodore Capital LP manages a concentrated, high-conviction portfolio totaling approximately $1.39 billion as of the report date September 30, 2025. The fund employs a focused investment strategy, holding only 26 securities, which indicates a preference for selecting specific winners rather than broad market diversification. The portfolio experienced a slight contraction of 1.8% in value during t...

The fund exhibits a distinct "barbell" structure in terms of position sizing. A single position, Merus N V, commands a dominant 23.85% of the portfolio, representing a massive, high-conviction bet. The remaining 75% of the portfolio is distributed across the other 25 holdings, with most positions falling between 2% and 8%, suggesting a tiered approach where the fund manager allocates heavily to the best idea while maintaining meaningful exposure to a select list of other opportunities.

Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
RLAY
RELAY THERAPEUTICS INC
$225M12.0M13.4%
02
ELVN
ENLIVEN THERAPEUTICS INC
$166M3.3M9.9%
03
G01767105
ALKERMES PLC
$157M3.0M9.4%
04
COGT
COGENT BIOSCIENCES INC
$118M3.0M7.0%
05
AMLX
AMYLYX PHARMACEUTICALS INC
$101M5.7M6.0%
06
DFTX
DEFINIUM THERAPEUTICS INC
$94M2.0M5.6%
07
SYRE
SPYRE THERAPEUTICS INC
$75M847K4.5%
08
ANRO
ALTO NEUROSCIENCE INC
$72M2.7M4.3%
09
TNGX
TANGO THERAPEUTICS INC
$70M2.3M4.2%
10
EYPT
EYEPOINT INC
$66M4.6M3.9%

Filing history

2026Q2Jun 30
$1.7B 2.9%
33 positionsView →
2026Q1Mar 31
$1.7B 15.1%
36 positionsView →
2025Q4Dec 31
$1.5B 8.0%
33 positionsView →
2025Q3Sep 30
$1.4B 1.8%
26 positionsView →
2025Q2Jun 30
$1.4B 44.4%
33 positionsLocked
2025Q1Mar 31
$981M 28.1%
25 positionsLocked
2024Q4Dec 31
$1.4B 14.7%
31 positionsLocked
2024Q3Sep 30
$1.6B 9.2%
36 positionsLocked
2024Q2Jun 30
$1.5B 2.0%
35 positionsLocked
2024Q1Mar 31
$1.5B 30.7%
39 positionsLocked
2023Q4Dec 31
$1.1B 33.8%
32 positionsLocked
2023Q3Sep 30
$856M 3.9%
30 positionsLocked
Showing 12 of 23